The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. Keeping that in mind, here are three stocks that are likely overheated and some you should look into instead.
One-Month Return: +41.7%
Powering communications for tech giants like Microsoft, Google, and Zoom, Bandwidth (NASDAQ:BAND) provides cloud-based communications software and APIs that enable businesses to embed voice, messaging, and emergency services into their applications and platforms.
Why Does BAND Fall Short?
Sales trends were unexciting over the last two years as its 12% annual growth was below the typical software company
Bad unit economics and steep infrastructure costs are reflected in its gross margin of 39.1%, one of the worst among software companies
Static operating margin over the last year shows it couldn’t become more efficient
At $23.43 per share, Bandwidth trades at 0.8x forward price-to-sales. Dive into our free research report to see why there are better opportunities than BAND.
One-Month Return: +13%
Formed between the merger of Callaway and Topgolf, Callaway Golf Company (NYSE:CALY) sells golf equipment and operates technology-driven golf entertainment venues.
Why Should You Dump CALY?
Muted 5.3% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
Free cash flow margin is forecasted to shrink by 9.3 percentage points in the coming year, suggesting the company will consume more capital to keep up with its competitors
Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Callaway Golf Company’s stock price of $15.17 implies a valuation ratio of 31.1x forward P/E. Read our free research report to see why you should think twice about including CALY in your portfolio, it’s free.
One-Month Return: +10.9%
Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.
Why Are We Wary of JAZZ?
5.5% annual revenue growth over the last two years was slower than its healthcare peers
Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 26.8 percentage points
Earnings per share fell by 8% annually over the last five years while its revenue grew, partly because it diluted shareholders
